TY - JOUR
T1 - Circulating anti-Müllerian hormone and breast cancer risk
T2 - A study in ten prospective cohorts
AU - Ge, Wenzhen
AU - Clendenen, Tess V.
AU - Afanasyeva, Yelena
AU - Koenig, Karen L.
AU - Agnoli, Claudia
AU - Brinton, Louise A.
AU - Dorgan, Joanne F.
AU - Eliassen, A. Heather
AU - Falk, Roni T.
AU - Hallmans, Göran
AU - Hankinson, Susan E.
AU - Hoffman-Bolton, Judith
AU - Key, Timothy J.
AU - Krogh, Vittorio
AU - Nichols, Hazel B.
AU - Sandler, Dale P.
AU - Schoemaker, Minouk J.
AU - Sluss, Patrick M.
AU - Sund, Malin
AU - Swerdlow, Anthony J.
AU - Visvanathan, Kala
AU - Liu, Mengling
AU - Zeleniuch-Jacquotte, Anne
N1 - Funding Information:
Key words: breast cancer, anti-Mu€llerian hormone, AMH, nested case–control study Abbreviations: AMH: anti-Mu€llerian hormone; BGS: Breakthrough Generations Study; BMI: body mass index; CLUE II: Campaign Against Cancer and Heart Disease; CSB: Columbia, Missouri Serum Bank; CV: coefficient of variation; FTP: full-term pregnancy; NHS: Nurses’ Health Study; NHSII: Nurses’ Health Study II; NSMSC: Northern Sweden Mammography Screening Cohort; NYUWHS: New York University Women’s Health Study; ORDET: Hormones and Diet in the Etiology of Breast Cancer Additional Supporting Information may be found in the online version of this article. †W.G. and T.V.C. are co-first authors ‡M.L. and A.Z.-J. are co-last authors Grant sponsor: NIH; Grant number: R01 CA178949; Grant sponsor: Breast Cancer Now (to BGS); Grant sponsor: The Institute of Cancer Research (to BGS); Grant sponsor: The Royal Marsden (to BGS); Grant sponsor: NHS (Royal Marsden and the Institute of Cancer Research NIHR Biomedical Research Center to BGS); Grant sponsor: Cancer Research UK; Grant number: C570/A16491 (to Guernsey); Grant sponsor: National Cancer Institute; Grant numbers: UM1 CA186107, R01 CA49449 (to NHS); Grant sponsor: National Cancer Institute; Grant numbers: UM1 CA176726, R01 CA67262 (to NHSII); Grant sponsor: National Cancer Institute; Grant numbers: R01 CA098661, UM1 CA182934 (to NYUWHS); Grant sponsor: NIH; Grant numbers: P30 CA016087, P30 ES000260 (center grants supporting NYUWHS); Grant sponsor: NIH Intramural Research Program (to Sister Study); Grant sponsor: NIEHS; Grant number: Z01-ES044005 (to Sister Study; DPS); Grant sponsor: Avon Foundation for Women; Grant number: 02-2012-085 (to Sister Study; HBN and DPS) DOI: 10.1002/ijc.31249 History: Received 30 June 2017; Accepted 7 Dec 2017; Online 8 Jan 2018 Correspondence to: Anne Zeleniuch-Jacquotte, Department of Population Health, NYU School of Medicine, 650 First Avenue, Room 539, New York, NY 10016, USA, Tel.: 1-212-263-6512, Fax: 1-212-263-8570, E-mail: anne.jacquotte@nyumc.org
Publisher Copyright:
© 2018 UICC
PY - 2018/6/1
Y1 - 2018/6/1
N2 - A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case–control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH was measured using a high sensitivity enzyme-linked immunoabsorbent assay. Conditional logistic regression was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk with increasing AMH concentration (ptrend across quartiles <0.0001) after adjusting for breast cancer risk factors. The odds ratio (OR) for breast cancer in the top vs. bottom quartile of AMH was 1.60 (95% CI = 1.31–1.94). Though the test for interaction was not statistically significant (pinteraction = 0.15), the trend was statistically significant only for tumors positive for both estrogen receptor (ER) and progesterone receptor (PR): ER+/PR+: ORQ4–Q1 = 1.96, 95% CI = 1.46–2.64, ptrend <0.0001; ER+/PR−: ORQ4–Q1 = 0.82, 95% CI = 0.40–1.68, ptrend = 0.51; ER−/PR+: ORQ4–Q1 = 3.23, 95% CI = 0.48–21.9, ptrend = 0.26; ER−/PR−: ORQ4–Q1 = 1.15, 95% CI = 0.63–2.09, ptrend = 0.60. The association was observed for both pre- (ORQ4–Q1= 1.35, 95% CI = 1.05–1.73) and post-menopausal (ORQ4–Q1 = 1.61, 95% CI = 1.03–2.53) breast cancer (pinteraction = 0.34). In this large consortium study, we confirmed that AMH is associated with breast cancer risk, with a 60% increase in risk for women in the top vs. bottom quartile of AMH.
AB - A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case–control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH was measured using a high sensitivity enzyme-linked immunoabsorbent assay. Conditional logistic regression was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk with increasing AMH concentration (ptrend across quartiles <0.0001) after adjusting for breast cancer risk factors. The odds ratio (OR) for breast cancer in the top vs. bottom quartile of AMH was 1.60 (95% CI = 1.31–1.94). Though the test for interaction was not statistically significant (pinteraction = 0.15), the trend was statistically significant only for tumors positive for both estrogen receptor (ER) and progesterone receptor (PR): ER+/PR+: ORQ4–Q1 = 1.96, 95% CI = 1.46–2.64, ptrend <0.0001; ER+/PR−: ORQ4–Q1 = 0.82, 95% CI = 0.40–1.68, ptrend = 0.51; ER−/PR+: ORQ4–Q1 = 3.23, 95% CI = 0.48–21.9, ptrend = 0.26; ER−/PR−: ORQ4–Q1 = 1.15, 95% CI = 0.63–2.09, ptrend = 0.60. The association was observed for both pre- (ORQ4–Q1= 1.35, 95% CI = 1.05–1.73) and post-menopausal (ORQ4–Q1 = 1.61, 95% CI = 1.03–2.53) breast cancer (pinteraction = 0.34). In this large consortium study, we confirmed that AMH is associated with breast cancer risk, with a 60% increase in risk for women in the top vs. bottom quartile of AMH.
KW - AMH
KW - anti-Müllerian hormone
KW - breast cancer
KW - nested case–control study
UR - http://www.scopus.com/inward/record.url?scp=85041669379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041669379&partnerID=8YFLogxK
U2 - 10.1002/ijc.31249
DO - 10.1002/ijc.31249
M3 - Article
C2 - 29315564
AN - SCOPUS:85041669379
SN - 0020-7136
VL - 142
SP - 2215
EP - 2226
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 11
ER -